BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.